Abstracts

Clinical-Ethiological Profile and Therapeutic Response in 719 Mexican Epileptic Children.

Abstract number : 2.105
Submission category :
Year : 2000
Submission ID : 508
Source : www.aesnet.org
Presentation date : 12/2/2000 12:00:00 AM
Published date : Dec 1, 2000, 06:00 AM

Authors :
Matilde Ruiz - garca, Cristina Sosa de Martnez, Adalberto Gonzalez Astiazaran, Inst Nacional de Pediatric, Mexico City, Mexico.

RATIONALE:To determine clinical-ethiological characteristics and therapuetic response of epileptic outpatients in a third world country. METHODS:All patients who attended the Epileptic Clinic in the Instituto Nacional de Pediatr a, a third level facility in Mexico City, between march and june 1998 were selected. Clinical and therapeutic response data were registered. As ethiology was used as explanatory variable, three groups were formed: Group I idiopathic; Group II cryptogenic and Group III symptomatic. Statistical tests were two tailed with ?=0.05. RESULTS:719 patients were studied, 123 in Group I, 132 in Group II, and 464 in Group III. In Group I, 56% were female; in the remaining groups males prevailes. Mean onset age was: Group I,5.2 years(SD 3.7 years); Group II 1.9years (SD2.4), and Group III 2.8 (SD 3.1). Mean evolution time was 5.3 years (SD 4) for all groups. In Group I, 1.1 seizure/per patient were registered,1.5 in Group II and 1.2 in Group III. There were 341/578 generalized seizures in Group III. 197/ 378 were symptomatic partial seizures.Among the partial seizures 86 simple and 292 partial complex with or without generalization. The syndromatic distribution was as follows: In Group I absences were present in 10%, and Rolandic epilepsy in 5%; In Group II 31% had focal cryptogenic epilepsy, and in Group III 31% had generalized epilepsy and 27% focal epilepsy. Main ethiologies in Group III: Hypoxic ishemic encephalopathy, neuroinfections and cerebovascular diseases. 87%of Group I patients were under control,of these, 91% were without treatment or on monotherapy. Pharmacological control was achieved in 63% patients of Groups II and III, 50% were on monotherapy. Psychomotor development was normal in 108 patients (87%) of Group I. CONCLUSIONS:Generalized seizures and sypmtomatic varieties prevailed. Each of the following was statistically significant (P<0.0001), early onset in Group II and III (< 2 years) patients; female gender, appropiate epileptic control and normal psychomotor development for patients in Group I.